Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US
详细信息 查看全文
- 作者：Jorge A. Alfaro-Murilloa ; jorge.alfaro-murillo@yale.edu" class="auth_mail" title="E-mail the corresponding author ; Jeffrey P. Townsendb ; Alison P. Galvania
- 关键词：Cytomegalovirus (CMV) ; Vaccination ; Screening ; Transmission ; Model
- 刊名：Vaccine
- 出版年：2016
- 出版时间：4 January 2016
- 年：2016
- 卷：34
- 期：2
- 页码：225-229
- 全文大小：747 K
文摘
- •
Cytomegalovirus (CMV) infection is the leading cause of birth defects in the US.
- •
CMV vaccines targeting seronegative women are currently in clinical development.
- •
The optimal age for vaccination depends on the duration of vaccine protection.
- •
For most scenarios, it is optimal to vaccinate women from 19 to 21 years of age.
- •
If the duration of vaccine protection is short, it is optimal to vaccinate infants.